Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926368 | 0.86 | SIGMAR1 (0.39) | SIGMAR1HTR6DRD2HTR1AMEN1 | |
| SCHEMBL19944415 | 0.80 | SIGMAR1 (0.62) | SIGMAR1DRD2MEN1KMT2ANPSR1 | |
| SCHEMBL2922385 | 0.79 | SIGMAR1 (0.47) | SIGMAR1HTR6DRD2HTR1AMEN1 | |
| SCHEMBL11278195 | 0.79 | HTR7 (0.55) | SIGMAR1DRD2HTR1AMEN1KMT2A | |
| SCHEMBL2925103 | 0.76 | HTR1A (0.49) | SIGMAR1HTR6HTR1AMEN1KMT2A | |
| SCHEMBL14438052 | 0.75 | PPARG (0.51) | SIGMAR1MEN1KMT2A | |
| SCHEMBL2781318 | 0.75 | PPARG (0.44) | SIGMAR1HTR6DRD2HTR1AKMT2A | |
| SCHEMBL4941683 | 0.73 | QDPR (0.46) | MEN1KMT2ANPSR1 | |
| SCHEMBL29363627 | 0.73 | SIGMAR1 (0.60) | SIGMAR1DRD2HTR1A | |
| SCHEMBL17411300 | 0.73 | HTR1A (0.51) | SIGMAR1HTR6DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1419773-B1 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| US-6924374-B2 | Central nervous system disorders; psychological disorders | A. CARLSSON RESEARCH AB (SE) | 2005-08-02 | — | — | US | disclosed |
| EP-1419773-A2 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-1240143-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046146-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | SIGMAR1 5/4885HTR6 130/4885DRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.